Möchten Sie immer auf dem neuesten Stand bleiben?

InnSight Technology announced a $515,000 Social Impact Investment from the Richard King Mellon Foundation.

KNOXVILLE, Tenn., July 22, 2026 (GLOBE NEWSWIRE) -- VisiRose, Inc. (“VisiRose” or the “Company”), the clinical-stage ophthalmology subsidiary of Provectus Biopharmaceuticals, Inc. (“Provectus”)...

LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...

USPTO Allows Claims Covering Topical Metformin Eye-Drop Therapy for Retinal Degeneration, Including Age-Related Macular Degeneration Palm Beach Gardens, FL, July 16, 2026 (GLOBE NEWSWIRE) --...

Dublin, July 13, 2026 (GLOBE NEWSWIRE) -- The "Ophthalmology Devices Market Report 2026" has been added to ResearchAndMarkets.com's offering. The ophthalmology devices market has experienced...

Cross Keys Capital is pleased to announce it acted as the exclusive financial adviser to Solinsky Eye Care in its partnership with Refocus Eye Health.

FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimodCompany unveils NEPTUNE...

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...

ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic...